Clinical trials
catalyst calendar across sponsors →Studies where WHWK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, Balyasny Asset Management L.P., Point72 Asset Management, L.P., +2 more) · FINRA short interest 10.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsNCT07444814Determine Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: HWK-007 | Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC | 226 | Oct 2028 | ≤ 804 d | 2026-08-05 |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.NCT07470853Determine Maximum Tolerated Dose (MTD)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: HWK-016, MUCIN-16-targeted ADC, Bevacizumab | PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer | 265 | Feb 2028 | ≤ 559 d | 2026-08-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19